Fig 1: Kaempferol restored epithelial‐fibroblast homeostasis by suppressing fibroblast activation via ANXA1/FPR2 signaling upregulation. (A) Co‐IP analysis of specific binding between ANXA1 and FPR family members (FPR1, FPR2, and FPR3). Input: Lysates from fibroblasts co‐cultured with the indicated epithelial cell groups, probed for ANXA1, FPR1, FPR2, and FPR3. IP‐ANXA1: Immunoprecipitates from fibroblast lysates (co‐cultured with the indicated epithelial cell groups) using ANXA1 antibody, probed for FPR1, FPR2, and FPR3. (B) IF staining of ANXA1 and FPR2 expressions in fibroblasts (scale bar = 25 μm). (C) Western blot analysis of fibroblast activation markers (FAP, VIM, α‐SMA, and MMP1). (D) IF staining of α‐SMA expression in fibroblasts (scale bar = 25 μm). *p < 0.05 vs. OSF, # p < 0.05 vs. OSF + Kaempferol, and p < 0.05 vs. OSF + Kaempferol+sh‐NC. (E) IF staining of ANXA1 and FPR2 expressions in fibroblasts (scale bar = 25 μm). (F) Western blot analysis of fibroblast activation markers (FAP, VIM, α‐SMA, and MMP1). (G) IF staining of α‐SMA expression in fibroblasts (scale bar = 25 μm). Data are presented as mean ± SD (n = 3). *p < 0.05 vs. sh‐N C.
Fig 2: Kaempferol alleviated arecoline‐induced oral mucosal epithelial cell injury by binding and upregulating ANXA1. (A) Molecular docking conformations of kaempferol with human and rat ANXA1. (B) Cell viability assessed by CCK‐8 assay after 24 h treatment with various arecoline concentrations (0–0.30 mM). * p < 0.05 vs. 0 mM. (C) Western blot analysis of ANXA1 protein expression. (D) Cell viability assessed by CCK‐8 assay after 24 h treatment with various kaempferol concentrations (0–40 μM). *p < 0.05 vs. 0 μM. (E) Western blot analysis of ANXA1 following DARTS assay treatment. *p < 0.05 vs. Control, # p < 0.05 vs. Pronase. (F) Western blot analysis of ANXA1 degradation at indicated temperatures. *p < 0.05 vs. DMSO. (G) qRT‐PCR analysis of ANXA1 mRNA expression. *p < 0.05 vs. csh‐NC. (H) Western blot analysis of ANXA1 protein expression. (I) Flow cytometry analysis of apoptosis rate. (J) Western blot analysis of ZO‐1 and Occludin protein expressions. (K) ELISA measurement of inflammatory factors (IL‐6, IL‐1β, and TNF‐α) in cell supernatants. Data are presented as mean ± SD (n = 3). *p < 0.05 vs. Control, # p < 0.05 vs. OSF, and p < 0.05 vs. pOSF+Kaempferol+sh‐N C.
Fig 3: JDK and kaempferol promoted ANXA1 expression in the oral mucosa of OSF rats. (A) IHC staining analysis of ANXA1 distribution in oral mucosal tissues (100×, scale bar = 100 μm; 400×, scale bar = 25 μm). (B) qRT‐PCR analysis of ANXA1 mRNA expression in oral mucosal tissues. (C) Western blot analysis of ANXA1 protein expression in oral mucosal tissues. (D) ELISA measurement of ANXA1 concentration in serum. Data are presented as mean ± SD (n = 6). *p < 0.05 vs. Sham, # p < 0.05 vs. OSF.
Fig 4: ANXA1 knockdown reversed the inhibitory effects of JDK and kaempferol on neutrophil recruitment and collagen deposition in OSF rat oral mucosa. (A) HE staining analysis of morphological changes in oral mucosal tissues (100×, scale bar = 100 μm; 400×, scale bar = 25 μm). (B) Masson staining analysis of collagen fiber deposition in oral submucosa (100×, scale bar = 100 μm; 400×, scale bar = 25 μm). (C) Maximal mouth opening at different treatment time points post‐modeling. (D) ELISA analysis of ANXA1 concentration in serum. (E) Western blot analysis of fibroblast activation markers (FAP, VIM, α‐SMA, and MMP1) in oral mucosal tissues. (F) IF staining of Ly6G expression in oral mucosa (scale bar = 25 μm). (G) ELISA measurement of IL‐6, IL‐1β, and TNF‐α concentrations in serum. (H) IF co‐staining of ANXA1 and FAP in oral mucosa (scale bar = 25 μm). (I) Pearson correlation analysis between ANXA1 expression (in tissues and serum) and Ly6G, FAP levels, or maximal mouth opening. Data are presented as mean ± SD (n = 6). *p < 0.05 vs. OSF, # p < 0.05 vs. OSF + Kaempferol + sh‐NC.
Supplier Page from Fine Biotech Co., Ltd. for Rat Anxa1 (Annexin A1) ELISA Kit